Test drug CBX-12 in advanced cancers and monitor your response
Part of Cancer clinical trials.
This Phase 1 study tests how your body handles the drug CBX-12 in people with advanced solid cancers that have already tried prior treatments. It may help researchers learn safe dosing and how tumors respond, and you may be asked to provide biopsy samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has spread, confirmed by pathology (biopsy or surgery) and it got worse after at least one prior treatment
- You have measurable tumor spots that can be accurately measured on a CT/MRI scan or chest X-ray (or by exam for some node areas)
- A doctor can safely take a biopsy from your tumor (tumor site is biopsy-friendly)
- You are age 18 or older, and your body strength/activity level is limited but not too low (ECOG 0–2)
- Your blood counts and organ labs are within required ranges (or can meet them with supplements), including white blood cells, hemoglobin, platelets, liver tests, and kidney function
- You can provide bloodwork for study safety and agree to contraception rules if applicable, and you can sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
This trial tests a new drug called CBX-663 in people with certain blood cancers, solid tumors, or glioblastoma that have returned or not responded to standard treatment. It aims to see if the drug is safe and helps shrink or control the cancer.
This trial studies a new experimental drug called CBX-12 for children, teens, and young adults with solid tumors that have returned or are hard to treat. The drug is designed to target and kill cancer cells, and the study will find the best dose and see how well it works.
This Phase 1 trial tests kanitinib (CX1003), a new cancer medicine, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The goal is to find a safe dose and see early signs of tumor response.
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
This trial tests a new drug, DXC006, for people with advanced solid tumors or blood cancers like multiple myeloma and neuroblastoma that have not responded to standard treatments. The goal is to see if it is safe and effective.
Hear when a new Metastatic Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.